Health
Korda Health offers Sentinel, a rare disease foundation model that analyzes longitudinal medical records to identify patients 6-9 years before clinical suspicion arises. The platform supports clinical trial recruitment, real-world evidence generation, and commercial patient finding for pharmaceutical and biotechnology companies. Sentinel can be piloted on a new rare disease within weeks and distinguishes true rare disease patients from phenotypic mimics.
- Healthcare Technology
- Artificial Intelligence
- Digital Health
- Data & Analytics
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Rare disease patients wait years for a diagnosis they may never get, with diagnostic odysseys spanning multiple misdiagnoses and ineffective treatments. These patients already exist within the health system but remain unidentified, delaying access to appropriate care and complicating clinical trial recruitment and drug development.
Solution
Sentinel is a rare disease foundation model that reads longitudinal medical records and surfaces patients who match a rare disease pattern before clinical suspicion arises. The model distinguishes between rare diseases, healthy baselines, and phenotypic mimics, separating true rare disease patients from the common conditions they get mistaken for. This capability collapses the diagnostic odyssey by identifying patients 6-9 years earlier than traditional clinical pathways. The platform supports clinical trial recruitment and enrollment, real-world evidence generation, market expansion, and post-launch patient finding for rare disease programs.
Target Audience
Pharmaceutical and biotechnology companies running rare disease clinical trials, as well as research organizations seeking to accelerate patient identification for rare disease studies and post-launch programs.
Features
- Foundation model trained on longitudinal medical records to detect rare disease patterns
- Distinguishes rare diseases from healthy baselines and phenotypic mimics
- Identifies patients 6-9 years before clinical suspicion
- Scalable to new rare diseases, with pilot deployment possible within weeks
- Built for scalability and interoperability with existing health system data infrastructure
- Commercial patient finding and clinical trial recruitment & enrollment capabilities